Sprout Health Review: Pricing, Plans, and Real Results

Sprout Health provides compounded semaglutide and tirzepatide through a telehealth intake process that evaluates your health history, weight loss goals, current medications, and eligibility for GLP-1 treatment. Eligible patients receive a prescription from a licensed provider, and medication ships from a licensed 503B compounding facility. The standard titration protocol follows the established clinical approach: starting at a low dose to allow physiological adaptation, increasing every 4-8 weeks based on tolerance and response, aiming for the lowest effective dose that produces meaningful appetite suppression and weight loss. The starting dose of 0.25mg semaglutide weekly is deliberately sub-therapeutic - it does not produce significant appetite suppression, but it allows the gut and brain to adapt to the medication before more substantial doses are introduced. Sprout's approach to the titration timeline is patient-paced within clinical parameters. For patients experiencing significant GI side effects at a particular dose, providers can extend the time at that level before escalating. This individualization prevents the premature discontinuation that occurs when patients are pushed through the titration schedule faster than their physiology can adapt. Monthly provider check-ins are included in the subscription. Nutritional guidance is provided as part of the program - not one-on-one dietitian sessions, but evidence-based dietary information about protein intake, meal timing, and food choices that work with GLP-1 pharmacology rather than against it.

GLP-1 medications produce their best long-term results when patients use the appetite reduction effect to build sustainable dietary habits - not just eat less during treatment, but restructure their relationship with food. Clinical outcomes are meaningfully better for patients who receive behavioral support alongside GLP-1 medication.

The practical implications of this framing: Sprout's nutritional guidance emphasizes protein adequacy (which preserves lean mass during weight loss), dietary patterns that reduce insulin resistance, and meal structures that support the medication's mechanism rather than counteracting it. High-fat meals considerably worsen GI side effects and slow gastric emptying beyond what the medication alone produces. Dietary guidance that helps patients navigate this during the titration phase directly affects treatment outcomes.

The sustainability framing also shapes expectation-setting. Sprout communicates realistic timelines - meaningful weight loss in months, not weeks; continued improvement with appropriate dose escalation; and the honest acknowledgment that most patients need ongoing treatment to maintain results rather than achieving a permanent biological change.

This honesty about the long-term nature of GLP-1 treatment is a feature, not a bug, for patients who want to make an informed decision about whether to start.

Sprout offers compounded semaglutide and compounded tirzepatide as its primary treatment options. Both are weekly subcutaneous injections. The active ingredients are identical to those in branded Wegovy, Ozempic (semaglutide) and Zepbound, Mounjaro (tirzepatide). The difference is manufacturing pathway - compounded rather than brand-manufacturer produced, from 503B facilities rather than Novo Nordisk or Eli Lilly.

Semaglutide at Sprout follows the standard titration schedule from 0.25mg to maintenance doses of 1.0-2.4mg weekly. The clinical data from the STEP program showed 14.9% average body weight reduction over 68 weeks at 2.4mg.

Tirzepatide's dual GLP-1/GIP mechanism produced stronger outcomes in clinical trials - 20.9% average weight loss over 72 weeks in the SURMOUNT-1 trial. The tradeoff is that tirzepatide is newer, so the real-world clinical experience base is smaller, and the cost is typically higher than semaglutide.

Sprout providers discuss which medication is appropriate based on your health profile during the initial consultation. For most patients starting GLP-1 treatment for the first time, semaglutide is the recommended starting point given its longer track record and established safety profile. Patients who have previously tried semaglutide with insufficient response are natural candidates for tirzepatide.

Sprout Health's pricing is positioned at the competitive end of the compounded GLP-1 market. Compounded semaglutide starts at approximately $149 per month for the introductory dose. As doses increase through the titration schedule, pricing adjusts accordingly - typically $179-199 per month at mid-range doses and $209-229 per month at maintenance doses. Tirzepatide starts at approximately $199-249 per month.

The monthly subscription covers medication, shipping, provider check-ins, and access to the nutritional guidance resources. There are no add-on fees for the check-ins or for the between-appointment messaging support.

Sprout operates as a cash-pay platform. Compounded medications are not covered by insurance formularies, which is the standard for compounded GLP-1 platforms. Branded Wegovy or Zepbound may have insurance coverage through specific employer health plans - if you have potential insurance coverage for branded medications, a platform that helps with prior authorization might save money. For patients without such coverage, Sprout's pricing represents an 85% reduction versus branded Wegovy at $1,349 per month.

HSA and FSA cards are accepted, allowing pre-tax dollars to cover the cost. For a patient in the 24% tax bracket paying $199 per month, HSA use reduces the effective monthly cost to approximately $151.

Sprout provides nutritional guidance as part of the program. This is not one-on-one registered dietitian coaching - it is educational resources and evidence-based recommendations about dietary patterns that support GLP-1 treatment outcomes. The distinction matters for setting accurate expectations.

What the nutritional guidance covers: protein intake recommendations (the standard clinical guidance is 1.2-1.6 grams per kilogram of body weight daily to preserve lean muscle mass during GLP-1-driven weight loss), meal composition and timing that minimizes GI side effects, foods to limit during the titration phase, and hydration guidance that supports the medication's mechanisms.

The protein adequacy guidance deserves emphasis because inadequate protein intake during GLP-1 treatment is one of the most common clinical errors. The dramatic appetite suppression from semaglutide or tirzepatide makes it easy to eat too little overall, and particularly too little protein. Lean mass loss during this process reduces basal metabolic rate - making both initial weight loss and long-term maintenance more difficult. Deliberate protein intake is not optional support for GLP-1 treatment; it is a clinical necessity.

For patients who want more intensive dietary support - personalized meal planning, macronutrient tracking, or regular dietitian check-ins - supplementing Sprout's guidance with a registered dietitian independently would provide that depth. The cost is incremental but potentially meaningful for long-term outcomes.

GLP-1 side effects follow a predictable pattern that Sprout's clinical team helps patients navigate. Gastrointestinal symptoms - nausea, constipation, vomiting, diarrhea - are most common during dose escalation and typically resolve within 2-3 weeks at each new dose level. The pharmacological mechanism is straightforward: GLP-1 receptors are present throughout the gastrointestinal tract, and activating them slows motility and gastric emptying in ways that produce both the therapeutic appetite suppression and the adverse GI effects. The patient-paced titration philosophy at Sprout has direct implications for side effect management. Rather than moving to the next dose on a fixed schedule, Sprout providers can extend the time at a comfortable dose. For patients with significant nausea at 0.5mg, staying at that level for 8 weeks rather than 4 allows adaptation before escalation. This flexibility is clinically important because early discontinuation due to unmanaged side effects is the most common reason GLP-1 treatment fails to produce meaningful results. Specific guidance Sprout provides for managing common side effects: injecting at bedtime so nausea peaks during sleep, eating smaller high-protein low-fat meals, staying hydrated, and taking the injection at a consistent time each week. For constipation - the most underreported GLP-1 side effect - fiber intake, hydration, and if needed, osmotic laxatives like MiraLax with provider guidance. For patients with severe nausea that is not improving with dietary adjustments, Sprout providers can prescribe antiemetic medications (ondansetron, promethazine) to make the titration phase tolerable.

The STEP 4 trial extension demonstrated that patients who discontinued semaglutide after achieving weight loss regained approximately two-thirds of their lost weight within one year - confirming that GLP-1 therapy is most effective as a long-term maintenance treatment rather than a time-limited course.

For patients who plan to use Sprout long-term, the financial planning matters. At $149-229 per month, ongoing GLP-1 treatment is a meaningful recurring expense. Over five years at $200 per month, that is $12,000. Over ten years, $24,000. These numbers are substantially lower than the equivalent period on branded medication, but they are not trivial.

The sustainability question - can you maintain your results if you eventually stop the medication - depends on whether the appetite-suppressed period was used to build habits that can reduce the gap between your biological hunger drive and the caloric intake that maintains your goal weight. No medication makes that gap zero, but effective behavioral change during treatment can narrow it considerably. This is where Sprout's nutritional guidance has the most potential clinical value.

For patients approaching goal weight on Sprout, the conversation about maintenance dosing, dose reduction strategies, and long-term planning is part of what the monthly check-ins address.